Annals of Hematology

, Volume 88, Issue 2, pp 121–132 | Cite as

Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab

  • Thomas Elter
  • Janne J. Vehreschild
  • John Gribben
  • Oliver A. Cornely
  • Andreas Engert
  • Michael Hallek
Original Article


Infection is a significant cause of morbidity and death in patients with chronic lymphocytic leukemia (CLL). Increased infectious events may arise from the multiple courses of immunosuppressive therapy and progressive deterioration of a patient’s immune system over the course of disease. The humanized, anti-CD52 monoclonal antibody alemtuzumab (Campath or Campath-1H) has shown notable activity for both untreated and fludarabine-refractory CLL. The antibody not only targets malignant cells but also affects normal, healthy immune cells. The cumulative effects of the malignancy and successive courses of treatments adversely impinge on a patient’s defense response to certain bacterial, fungal, and viral infections. In this review article, we provide an overview of common infectious events associated with alemtuzumab therapy in CLL. We also discuss recommendations for effectively monitoring and managing infections in CLL patients.


Alemtuzumab Campath CLL Infection Management 



This manuscript was supported in part by the German Competence Network on Malignant Lymphoma (KML) of the BMB-F. Editorial assistance for this manuscript was provided by Meniscus Health Care Communications, with the financial support of Schering AG. JG is a speaker for Roche, Genentech and Schering AG/Berlex. OAC is supported by the German Federal Ministry of Research and Education (BMBF grant 01KN0706); has received research grants from Astellas, Basilea, Bayer, Genzyme, Gilead, Pfizer, Merck, Schering-Plough, and Vicuron; is a consultant to Astellas, Basilea, F2G, Gilead, Pfizer, Merck, Mölnlycke, Nektar, Schering-Plough, and Zeneus; and served at the speakers’ bureau of Astellas, Gilead, Merck, Schering-Plough, SpePharm, and United Medical.


JJV received Travel grants from Astellas, Gilead, Merck, Pfizer, Schering-Plough, and Viropharma. TE, AE, MH received travel, speaker and research grants from BayerSchering.


  1. 1.
    Akova M, Paesmans M, Calandra T, Viscoli C (2005) A European organization for research and treatment of cancer—International Antimicrobial Therapy Group Study of secondary infections in febrile, neutropenic patients with cancer. Clin Infect Dis 40:239–245PubMedCrossRefGoogle Scholar
  2. 2.
    Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E, Knolle PA, Thomas RK, von Bergwelt-Baildon M, Debey S, Hallek M, Schultze JL (2005) Reduced frequencies and suppressive function of CD4+ CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 106:2018–2025PubMedCrossRefGoogle Scholar
  3. 3.
    Briggs PG, Kraft N, Atkins RC (1990) T cells and CD45R expression in B-chronic lymphocytic leukemia. Leuk Res 14:155–159PubMedCrossRefGoogle Scholar
  4. 4.
    Caillot D, Couaillier JF, Bernard A, Casasnovas O, Denning DW, Mannone L, Lopez J, Couillault G, Piard F, Vagner O, Guy H (2001) Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 19:253–259PubMedGoogle Scholar
  5. 5.
    Chakrabarti S, MacDonald D, Hale G, Holder K, Turner V, Czarnecka H, Thompson J, Fegan C, Waldmann H, Milligan DW (2003) T-cell depletion with Campath-1H “in the bag” for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival. Br J Haematol 121:109–118PubMedCrossRefGoogle Scholar
  6. 6.
    Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S, Geary J, Thuraisundaram D, Branson K, Chakrabarti S, Mahendra P, Craddock C, Parker A, Hunter A, Hale G, Waldmann H, Williams CD, Yong K, Linch DC, Goldstone AH, Mackinnon S (2002) Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 99:1071–1078PubMedCrossRefGoogle Scholar
  7. 7.
    Cornely OA, Bohme A, Buchheidt D, Glasmacher A, Kahl C, Karthaus M, Kern W, Kruger W, Maschmeyer G, Ritter J, Salwender HJ, Sandherr M, Schiel X, Schuttrumpf S, Sieniawski M, Silling G, Ullmann AJ, Wolf HH (2003) Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 82(Suppl 2):S186–S200PubMedCrossRefGoogle Scholar
  8. 8.
    Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, Heussel CP, Lortholary O, Rieger C, Boehme A, Aoun M, Horst HA, Thiebaut A, Ruhnke M, Reichert D, Vianelli N, Krause SW, Olavarria E, Herbrecht R (2007) Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 44:1289–1297PubMedCrossRefGoogle Scholar
  9. 9.
    Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, -Gonzalez D (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356:348–359PubMedCrossRefGoogle Scholar
  10. 10.
    Delgado J, Thomson K, Russell N, Ewing J, Stewart W, Cook G, Devereux S, Lovell R, Chopra R, Marks DI, Mackinnon S, Milligan DW (2006) Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood 107:1724–1730PubMedCrossRefGoogle Scholar
  11. 11.
    Eichhorst BF, Busch R, Schweighofer C, Wendtner CM, Emmerich B, Hallek M (2007) Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy. Br J Haematol 136(1):63–72PubMedCrossRefGoogle Scholar
  12. 12.
    Elter T, Borchmann P, Schulz H, Reiser M, Trelle S, Schnell R, Jensen M, Staib P, Schinkothe T, Stutzer H, Rech J, Gramatzki M, Aulitzky W, Hasan I, Josting A, Hallek M, Engert A (2005) Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 23:7024–7031PubMedCrossRefGoogle Scholar
  13. 13.
    Ferrajoli A, O’Brien SM, Cortes JE, Giles FJ, Thomas DA, Faderl S, Kurzrock R, Lerner S, Kontoyiannis DP, Keating MJ (2003) Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 98:773–778PubMedCrossRefGoogle Scholar
  14. 14.
    Fischer K, Schweighofer CD, Ritgen M, Bottcher S, Scharf E, Eichhorst BF, Busch R, Abenhardt W, Kneba M, Hallek M, Wendtner CM, the German CLL Study Group (2007) Dose-escalation study to evaluate dose limiting toxicity (DLT), maximum tolerated dose (MTD) and safety of alemtuzumab for consolidation therapy in patients with chronic lymphocytic leukemia: phase I/II trial of the German CLL Study Group (GCLLSG) [abstract 2053]. Blood 110:612aGoogle Scholar
  15. 15.
    Francis S, Karanth M, Pratt G, Starczynski J, Hooper L, Fegan C, Pepper C, Valcarcel D, Milligan DW, Delgado J (2006) The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. Cancer 107:1023–1033PubMedCrossRefGoogle Scholar
  16. 16.
    Gamadia LE, Rentenaar RJ, Baars PA, Remmerswaal EB, Surachno S, Weel JF, Toebes M, Schumacher TN, IJ ten Berge, Van Lier RA (2001) Differentiation of cytomegalovirus-specific CD8(+) T cells in healthy and immunosuppressed virus carriers. Blood 98:754–761PubMedCrossRefGoogle Scholar
  17. 17.
    Gilleece MH, Dexter TM (1993) Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 82:807–812PubMedGoogle Scholar
  18. 18.
    Gorgun G, Holderried TA, Zahrieh D, Neuberg D, Gribben JG (2005) Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest 115:1797–1805PubMedCrossRefGoogle Scholar
  19. 19.
    Hale G, Bright S, Chumbley G, Hoang T, Metcalf D, Munro AJ, Waldmann H (1983) Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 62:873–882PubMedGoogle Scholar
  20. 20.
    Hale G, Cobbold S, Waldmann H (1988) T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation. Transplantation 45:753–759PubMedCrossRefGoogle Scholar
  21. 21.
    Hensel M, Kornacker M, Yammeni S, Egerer G, Ho AD (2003) Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia. Br J Haematol 122:600–606PubMedCrossRefGoogle Scholar
  22. 22.
    Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de PB (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415PubMedCrossRefGoogle Scholar
  23. 23.
    Heussel CP, Kauczor HU, Heussel GE, Fischer B, Begrich M, Mildenberger P, Thelen M (1999) Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. J Clin Oncol 17:796–805PubMedGoogle Scholar
  24. 24.
    Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J, Sirard C, Mayer J (2007) Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25:5616–5623PubMedCrossRefGoogle Scholar
  25. 25.
    Hooper M, Kallas EG, Coffin D, Campbell D, Evans TG, Looney RJ (1999) Cytomegalovirus seropositivity is associated with the expansion of CD4+. J Rheumatol 26:1452–1457PubMedGoogle Scholar
  26. 26.
    Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751PubMedCrossRefGoogle Scholar
  27. 27.
    Itala M, Helenius H, Nikoskelainen J, Remes K (1992) Infections and serum IgG levels in patients with chronic lymphocytic leukemia. Eur J Haematol 48:266–270PubMedCrossRefGoogle Scholar
  28. 28.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43–66PubMedGoogle Scholar
  29. 29.
    Keating M, Coutre S, Rai K, Osterborg A, Faderl S, Kennedy B, Kipps T, Bodey G, Byrd JC, Rosen S, Dearden C, Dyer MJ, Hillmen P (2004) Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma 4:220–227PubMedCrossRefGoogle Scholar
  30. 30.
    Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99:3554–3561PubMedCrossRefGoogle Scholar
  31. 31.
    Kruger WH, Bohlius J, Cornely OA, Einsele H, Hebart H, Massenkeil G, Schuttrumpf S, Silling G, Ullmann AJ, Waldschmidt DT, Wolf HH (2005) Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Oncology. Ann Oncol 16:1381–1390PubMedCrossRefGoogle Scholar
  32. 32.
    Lin TS, Donohue KA, Lucas MS et al (2007) Consolidation therapy with subcutaneous (SC) alemtuzumab results in severe infectious toxicity in previously untreated CLL patients who achieve a complete response (CR) after fludarabine and rituximab (FR) induction therapy: interim safety analysis of the CALGB Study 10101 [abstract 755]. Blood 110:232aGoogle Scholar
  33. 33.
    Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V, Mollgard L, Rebello P, Hale G, Waldmann H, Mellstedt H, Osterborg A (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100:768–773PubMedCrossRefGoogle Scholar
  34. 34.
    Lundin J, Porwit-MacDonald A, Rossmann ED, Karlsson C, Edman P, Rezvany MR, Kimby E, Osterborg A, Mellstedt H (2004) Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 18:484–490PubMedCrossRefGoogle Scholar
  35. 35.
    Mackus WJ, Frakking FN, Grummels A, Gamadia LE, De Bree GJ, Hamann D, Van Lier RA, Van Oers MH (2003) Expansion of CMV-specific CD8+CD45RA+. Blood 102:1057–1063PubMedCrossRefGoogle Scholar
  36. 36.
    Molteni A, Nosari A, Montillo M, Cafro A, Klersy C, Morra E (2005) Multiple lines of chemotherapy are the main risk factor for severe infections in patients with chronic lymphocytic leukemia with febrile episodes. Haematologica 90:1145–1147PubMedGoogle Scholar
  37. 37.
    Montillo M, Tedeschi A, Miqueleiz S, Veronese S, Cairoli R, Intropido L, Ricci F, Colosimo A, Scarpati B, Montagna M, Nichelatti M, Regazzi M, Morra E (2006) Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 24:2337–2342PubMedCrossRefGoogle Scholar
  38. 38.
    Moreton P, Kennedy B, Lucas G, Leach M, Rassam SM, Haynes A, Tighe J, Oscier D, Fegan C, Rawstron A, Hillmen P (2005) Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23:2971–2979PubMedCrossRefGoogle Scholar
  39. 39.
    Nabhan C, Gartenhaus RB, Tallman MS (2004) Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era. Leuk Res 28:429–442PubMedCrossRefGoogle Scholar
  40. 40.
    Nguyen DD, Cao TM, Dugan K, Starcher SA, Fechter RL, Coutre SE (2002) Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clin Lymphoma 3:105–110PubMedCrossRefGoogle Scholar
  41. 41.
    Nuckel H, Frey UH, Roth A, Duhrsen U, Siffert W (2005) Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. Eur J Pharmacol 514:217–224PubMedGoogle Scholar
  42. 42.
    O’Brien SM, Kantarjian HM, Thomas DA, Cortes J, Giles FJ, Wierda WG, Koller CA, Ferrajoli A, Browning M, Lerner S, Albitar M, Keating MJ (2003) Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 98:2657–2663PubMedCrossRefGoogle Scholar
  43. 43.
    O’Brien SM, Keating MJ, Mocarski ES (2006) Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma 7:125–130PubMedCrossRefGoogle Scholar
  44. 44.
    O’Brien S, Ravandi F, Riehl T, Wierda W, Huang X, Tarrand J, O’Neal B, Kantarjian H, Keating M (2008) Valganciclovir prevents CMV reactivation in patients receiving alemtuzumab based therapy. Blood 111(4):1816–1819PubMedCrossRefGoogle Scholar
  45. 45.
    Oscier D, Fegan C, Hillmen P, Illidge T, Johnson S, Maguire P, Matutes E, Milligan D (2004) Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol 125:294–317PubMedCrossRefGoogle Scholar
  46. 46.
    Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, Mellstedt H (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 15:1567–1574PubMedGoogle Scholar
  47. 47.
    Perkins JG, Flynn JM, Howard RS, Byrd JC (2002) Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 94:2033–2039PubMedCrossRefGoogle Scholar
  48. 48.
    Pettitt AR, Matutes E, Oscier D (2006) Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 20:1441–1445PubMedCrossRefGoogle Scholar
  49. 49.
    Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, Santabarbara P, Wacker B, Brettman L (2002) Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 20:3891–3897PubMedCrossRefGoogle Scholar
  50. 50.
    Ravandi F, O’Brien S (2005) Alemtuzumab. Expert Rev Anticancer Ther 5:39–51PubMedCrossRefGoogle Scholar
  51. 51.
    Redaelli A, Laskin BL, Stephens JM, Botteman MF, Pashos CL (2004) The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care (Engl) 13:279–287CrossRefGoogle Scholar
  52. 52.
    Robak T (2004) Monoclonal antibodies in the treatment of chronic lymphoid leukemias. Leuk Lymphoma 45:205–219PubMedCrossRefGoogle Scholar
  53. 53.
    Sandherr M, Einsele H, Hebart H, Kahl C, Kern W, Kiehl M, Massenkeil G, Penack O, Schiel X, Schuettrumpf S, Ullmann AJ, Cornely OA (2006) Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol 17:1051–1059PubMedCrossRefGoogle Scholar
  54. 54.
    Schweighofer C, Ritgen M, Eichhorst B, Busch R, Kneba M, Hallek M, Wendtner C, the German CLL Study Group (2006) Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL study group (GCLLSG). Blood 108:33 AbstractGoogle Scholar
  55. 55.
    Stanglmaier M, Reis S, Hallek M (2004) Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol 83:634–645PubMedCrossRefGoogle Scholar
  56. 56.
    Tsiodras S, Samonis G, Keating MJ, Kontoyiannis DP (2000) Infection and immunity in chronic lymphocytic leukemia. Mayo Clin Proc 75:1039–1054PubMedGoogle Scholar
  57. 57.
    Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de AW, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356:335–347PubMedCrossRefGoogle Scholar
  58. 58.
    Waldmann H, Polliak A, Hale G, Or R, Cividalli G, Weiss L, Weshler Z, Samuel S, Manor D, Brautbar C (1984) Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 2:483–486PubMedCrossRefGoogle Scholar
  59. 59.
    Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351:1391–1402PubMedCrossRefGoogle Scholar
  60. 60.
    Warkentin DI, Epstein JB, Campbell LM, Yip JG, Cox VC, Ransier A, Barnett MJ, Marra F (2002) Valacyclovir versus acyclovir for HSV prophylaxisin neutropenic patients. Ann Pharmacother 36:1525–1531PubMedCrossRefGoogle Scholar
  61. 61.
    Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jager G, Eichhorst B, Busch R, Diem H, Engert A, Stilgenbauer S, Dohner H, Kneba M, Emmerich B, Hallek M (2004) Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 18:1093–1101PubMedCrossRefGoogle Scholar
  62. 62.
    Wierda W, O’Brien S, Faderl S, Ferrajoli A, Wang X, Do KA, Garcia-Manero G, Thomas D, Cortes J, Ravandi-Kashani F, Giles F, Lerner S, Kantarjian H, Keating M (2006) A retrospective comparison of three sequential groups of patients with recurrent/refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 106:337–345PubMedCrossRefGoogle Scholar
  63. 63.
    Zent CS, Chen JB, Kurten RC, Kaushal GP, Marie LH, Schichman SA (2004) Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. Leuk Res 28:495–507PubMedCrossRefGoogle Scholar
  64. 64.
    Zenz T, Ritgen M, Dreger P, Krober A, Barth TF, Schlenk R, Bottcher S, Hallek MJ, Kneba M, Bunjes D, Dohner H, Stilgenbauer S (2006) Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 108:2127–2130PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Thomas Elter
    • 1
  • Janne J. Vehreschild
    • 1
  • John Gribben
    • 2
  • Oliver A. Cornely
    • 1
    • 3
  • Andreas Engert
    • 1
  • Michael Hallek
    • 1
  1. 1.Department of Hematology, Oncology and Infectious DiseasesUniversity of CologneCologneGermany
  2. 2.Cancer Research UKBarts and the London School of MedicineLondonUK
  3. 3.Center for Clinical TrialsUniversity of CologneCologneGermany

Personalised recommendations